Current Report Filing (8-k)
15 February 2023 - 9:30AM
Edgar (US Regulatory)
0001053369
false
0001053369
2023-02-14
2023-02-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
February
14, 2023
Date
of Report (Date of earliest event reported)
ELITE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
001-15697 |
|
22-3542636 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
165
Ludlow Avenue, Northvale, New Jersey 07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value
$0.001 per share |
|
ELTP |
|
OTCQB |
Item
2.02. Results of Operations and Financial Condition.
On
February 14, 2023, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) filed its quarterly report on Form
10-Q for the quarter ended December 31, 2022, and issued a press release announcing its financial results for that quarter. A copy of
the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As
noted in the press release, the Company will host a conference call at 11:30 AM Eastern Standard Time (EST) on Wednesday, February 15,
2023, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.
Conference
Call Information
Date: |
February 15, 2023 |
Time: |
11:30 AM EST |
Dial-in numbers: |
1-800-346-7359 (domestic) |
|
1-973-528-0008 (international) |
Conference number: |
98840 |
Questions: |
dianne@elitepharma.com |
|
Financial questions by 7:00 PM EST on Tuesday, February
14, 2023. |
Audio Replay: |
https://elite.irpass.com/events_presentations |
Item
7.01 Regulation FD Disclosure.
The
information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form
8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item
7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the
information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall
it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report
(including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely
to satisfy the requirements of Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: February 14, 2023 |
ELITE PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/
Nasrat Hakim |
|
|
Nasrat Hakim, President and CEO |
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Sep 2023 to Sep 2024